nonrecommended AVF was created (AVG, 36; AVF, 17). Excluded were 25 patients who were lost to follow-up, died early, or never started dialysis. The functional maturation rate for AVF recommended by the VAPS was 78% (matured, 75; failed, 21). At least one intervention was required in 29% (22 of 75) of matured fistulas required to achieve maturation. The maturation rate for AVF not recommended by the VAPS was 62% (matured, 8; failed, 5).
VESS15.

Association of Variant Arch
Objectives: Aortic arch embryologic variations are more common in patients with thoracic aortic disease for reasons unknown. Additionally, little is understood about their relation to type B dissections (TBAD) specifically. We investigated the prevalence of variant aortic arches in patients with TBAD compared to controls. In order to understand the implications of a variant aortic arch anatomy to degenerative aortic disease, we compared flow hemodynamics of three variations of aortic arches using four-dimensional (4D) flow magnetic resonance imaging (4D Flow MRI).
Methods: A cohort of patients with TBAD was age/gender matched with controls free of aortic pathology. Arch variants were defined and assessed: common origin of innominate and left common carotid artery (bovine arch and truncus bicaroticus), aberrant right subclavian artery (SCA), and right-sided aortic arch. Demographics and TBAD characteristics were abstracted, and TBAD patients with variant and conventional aortic arches were compared. Additionally, three matched healthy controls with conventional, bovine, and aberrant right SCA arches underwent 4D flow MRI evaluation. Indices of regional hemodynamic wall sheer stress (WSS) were compared (systolic WSS, time-averaged WSS [TA-WSS] , and oscillatory shear index [OSI]).
Results: Computed tomography scans of 185 consecutive TBAD patients (72.4% males, 71% Caucasian) and 367 controls (67% males, 78% Caucasian) were reviewed. Variant arch anatomy was significantly more prevalent in TBAD patients (39.5% vs 22.6%; P < .0001). Among those with TBAD, the mean age of presentation and descending thoracic aorta (DTA) diameter were similar whether they had variant or conventional aortic arches (Table) . The most common arch variant was the bovine arch (37.3% vs 22.3% controls; P < .0001) and was associated with a higher prevalence of dissection entry tears proximal to the left SCA (12.7% vs 6.6% distal; P ¼ .178). 4D flow MRI demonstrated hemodynamic variations between arch types: The bovine arch had the highest systolic WSS along the inner curve, TA-WSS in zone 1, and OSI in zone 2 (Fig) . The conventional arch had the lowest TA-WSS, while the aberrant RSCA arch had the lowest OSI.
Conclusions: Variant aortic arch anatomy is significantly more prevalent in TBAD patients in this predominantly Caucasian population. The bovine arch demonstrated hemodynamic flow alterations typically associated with endothelial injury and vascular stiffness. This could potentially explain the higher prevalence of variant arch anatomy in TBAD patients. Studies of long-term outcomes based on arch anatomy and 4D flow MRI in TBAD will offer additional insight to TBAD genesis and may influence management decisions.
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VESS16.
Study to Assess Outcomes for Multiple TEVAR Pathologies (SUMMIT) Registry 
Cook Research Incorporated
Objectives: Thoracic endovascular aortic repair (TEVAR) is currently the treatment of choice for most pathologies of the descending thoracic aorta. Using data from the Cook SUMMIT registry, we aim to investigate the outcomes of TEVAR for the treatment of different pathologies within instructions for use (IFU) and understand predictive factors affecting outcomes.
Methods: The SUMMIT registry includes aggregated data of 521 TEVAR patients from five prospective, multicenter trials evaluating thoracic endografts of the Zenith platform (Cook Medical, Bloomington, Ind): Zenith TX2 pivotal study, TX2 postapproval study, Zenith Alpha Thoracic study, TRANSFIX study, and STABLE I study. Primary outcomes of this post hoc analysis include 30-day and 1-year mortality and morbidity, and cumulative mortality and reinterventions. Cox regression analyses were performed to identify risk factors for mortality and reinterventions. Results: Of the 521 total patients (67% male; age, 67.2 6 15 years), 329 were treated for thoracic aortic aneurysms (TAA), 56 for thoracic ulcers, 55 for acute and 31 for nonacute type B aortic dissections (TBAD), and 50 for blunt thoracic aortic injuries (BTAI). Overall 30-day mortality was 1.7%, with a perioperative stroke rate of 3.1%, a paraplegia rate of 1.2%, and a proximal type I endoleak rate of 0.4% (Table) . Cumulative 1-year mortality was 8.1%. Kaplan-Meier curves of all-cause mortality are presented in the Fig. Multivariate analysis identified age (hazard ratio [HR] , 1.04), congestive heart failure (HR, 2.87), serum creatinine (HR. 1.19 per 1 mg/dL), iliac tortuosity (HR, 1.32), and blood transfusion (HR 1.59 per 500 mL packed red blood cells [PRBC] ); and 30-day stroke (HR, 3.93), paraplegia (HR, 7.79), and paraparesis (HR, 2.46) as significant predictors for all-cause mortality. Patients treated for dissection, but not TAA or BTAI, demonstrated significantly higher risk for reintervention (acute TBAD HR, 5.65; nonacute TBAD HR, 6.60) as compared to patients treated for thoracic ulcers (reference group). Intraoperative contrast (HR. 1.31 per 100 mL) and blood transfusion volumes (HR, 1.42 per 500 mL PRBC), surrogates of case complexity, were also significant predictors for reintervention.
Conclusions: For patients treated in accordance with the IFU, the 30-day results of TEVAR within these clinical trials demonstrate exceptionally low mortality and stroke rates. Acute and nonacute TBAD are associated with a higher risk for reintervention, possibly attributed to the natural history of the disease, while age, reduced cardiac and renal functions, complex access, intraoperative transfusion, and early neurologic complications after TEVAR are associated with higher cumulative mortality. Follow-up, mean 6 SD, years 4.0 6 1.8 3.8 6 1.9 2.0 6 1.2 3.0 6 1.7 3.1 6 1.5 3.1 6 1.7
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